255 related articles for article (PubMed ID: 2106164)
21. Population pharmacokinetics of cyclophosphamide and its metabolites 4-hydroxycyclophosphamide, 2-dechloroethylcyclophosphamide, and phosphoramide mustard in a high-dose combination with Thiotepa and Carboplatin.
de Jonge ME; Huitema AD; van Dam SM; Rodenhuis S; Beijnen JH
Ther Drug Monit; 2005 Dec; 27(6):756-65. PubMed ID: 16306851
[TBL] [Abstract][Full Text] [Related]
22. Novobiocin in combination with high-dose chemotherapy for the treatment of advanced breast cancer: a phase 2 study.
Hahm HA; Armstrong DK; Chen TL; Grochow L; Passos-Coelho J; Goodman SN; Davidson NE; Kennedy MJ
Biol Blood Marrow Transplant; 2000; 6(3A):335-43. PubMed ID: 10905771
[TBL] [Abstract][Full Text] [Related]
23. A preclinical model for sequential high-dose chemotherapy.
Holden SA; Teicher BA; Ayash LJ; Frei E
Cancer Chemother Pharmacol; 1995; 36(1):61-4. PubMed ID: 7720177
[TBL] [Abstract][Full Text] [Related]
24. Interaction of D,L- and D-tetraplatin with hyperthermia in vitro and in vivo.
Epelbaum R; Teicher BA; Holden SA; Ara G; Varshney A; Herman TS
Eur J Cancer; 1992; 28A(4-5):794-800. PubMed ID: 1524897
[TBL] [Abstract][Full Text] [Related]
25. Modulation of alkylating agents by lonidamine in vivo.
Teicher BA; Holden SA; Herman TS; Frei E
Semin Oncol; 1991 Apr; 18(2 Suppl 4):7-10. PubMed ID: 1903216
[TBL] [Abstract][Full Text] [Related]
26. The effect of fluosol-DA and oxygenation status on the activity of cyclophosphamide in vivo.
Teicher BA; Herman TS; Holden SA; Cathcart KN
Cancer Chemother Pharmacol; 1988; 21(4):286-91. PubMed ID: 3131033
[TBL] [Abstract][Full Text] [Related]
27. A search for new metabolites of N,N',N''-triethylenethiophosphoramide.
van Maanen MJ; Tijhof IM; Damen JM; Versluis C; van den Bosch JJ; Heck AJ; Rodenhuis S; Beijnen JH
Cancer Res; 1999 Sep; 59(18):4720-4. PubMed ID: 10493531
[TBL] [Abstract][Full Text] [Related]
28. Synergistic anti-tumor activity of a novel immunomodulator, BCH-1393, in combination with cyclophosphamide.
Kadhim S; Penney C; Lagraoui M; Heibein J; Attardo G; Zacharie B; Connolly T; Gagnon L
Int J Immunopharmacol; 2000 Sep; 22(9):659-71. PubMed ID: 10884587
[TBL] [Abstract][Full Text] [Related]
29. Effects of various oxygenation conditions on the enhancement by Fluosol-DA of melphalan antitumor activity.
Teicher BA; Crawford JM; Holden SA; Cathcart KN
Cancer Res; 1987 Oct; 47(19):5036-41. PubMed ID: 3113727
[TBL] [Abstract][Full Text] [Related]
30. Combination intraventricular therapy with thiotepa and cytarabine in meningeal carcinomatosis due to breast cancer: in vitro evidence for supra-additive cytotoxicity.
Liebmann J; Gurtler J
Anticancer Drugs; 1995 Feb; 6(1):40-4. PubMed ID: 7756682
[TBL] [Abstract][Full Text] [Related]
31. Sequence dependence of paclitaxel (Taxol) combined with cisplatin or alkylators in human cancer cells.
Liebmann JE; Fisher J; Teague D; Cook JA
Oncol Res; 1994; 6(1):25-31. PubMed ID: 7919549
[TBL] [Abstract][Full Text] [Related]
32. Classification of antineoplastic treatments by their differential toxicity toward putative oxygenated and hypoxic tumor subpopulations in vivo in the FSaIIC murine fibrosarcoma.
Teicher BA; Holden SA; al-Achi A; Herman TS
Cancer Res; 1990 Jun; 50(11):3339-44. PubMed ID: 2334928
[TBL] [Abstract][Full Text] [Related]
33. Urinary excretion of thioTEPA and its metabolites in patients treated with high-dose cyclophosphamide, thioTEPA and carboplatin.
van Maanen MJ; Huitema AD; Rodenhuis S; Beijnen JH
Anticancer Drugs; 2001 Jul; 12(6):519-24. PubMed ID: 11459998
[TBL] [Abstract][Full Text] [Related]
34. A phase I-II study of cyclophosphamide, thiotepa, and carboplatin with autologous bone marrow transplantation in solid tumor patients.
Eder JP; Elias A; Shea TC; Schryber SM; Teicher BA; Hunt M; Burke J; Siegel R; Schnipper LE; Frei E
J Clin Oncol; 1990 Jul; 8(7):1239-45. PubMed ID: 2162912
[TBL] [Abstract][Full Text] [Related]
35. Antitumor efficacy and pharmacokinetic analysis of 4-hydroperoxycyclophosphamide in comparison with cyclophosphamide +/- hepatic enzyme effectors.
Teicher BA; Holden SA; Goff DA; Wright JE; Tretyakov O; Ayash LJ
Cancer Chemother Pharmacol; 1996; 38(6):553-60. PubMed ID: 8823498
[TBL] [Abstract][Full Text] [Related]
36. Effects of the mode of administration of mitomycin on tumor and marrow response and on the therapeutic ratio.
Rockwell S; Nierenburg M; Irvin CG
Cancer Treat Rep; 1987 Oct; 71(10):927-34. PubMed ID: 3652056
[TBL] [Abstract][Full Text] [Related]
37. Effect of glutathione depletion by L-buthionine sulfoximine on the cytotoxicity of cyclophosphamide in single and fractionated doses to EMT6/SF mouse tumors and bone marrow.
Ono K; Shrieve DC
J Natl Cancer Inst; 1987 Oct; 79(4):811-5. PubMed ID: 3477662
[TBL] [Abstract][Full Text] [Related]
38. Accuracy, feasibility, and clinical impact of prospective Bayesian pharmacokinetically guided dosing of cyclophosphamide, thiotepa, and carboplatin in high-dose chemotherapy.
de Jonge ME; Huitema AD; Tukker AC; van Dam SM; Rodenhuis S; Beijnen JH
Clin Cancer Res; 2005 Jan; 11(1):273-83. PubMed ID: 15671556
[TBL] [Abstract][Full Text] [Related]
39. Chemotherapy with [SP-4-3-(R)]-[1,1-cyclobutanedicarboxylato(2-)](2- methyl-1,4-butanediamine-N,N')platinum (CI-973, NK121) in combination with standard agents against murine tumors in vivo.
Elliott WL; Roberts BJ; Howard CT; Leopold WR
Cancer Res; 1994 Aug; 54(16):4412-8. PubMed ID: 8044790
[TBL] [Abstract][Full Text] [Related]
40. Synergistic interaction between cyclophosphamide or paclitaxel and the bioreductive compound NLCPQ-1, in vivo.
Papadopoulou MV; Ji M; Bloomer WD
Oncol Res; 2003; 13(12):561-6. PubMed ID: 12899246
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
